Athira Pharma ATHA Stock
Athira Pharma Price Chart
Athira Pharma ATHA Financial and Trading Overview
Athira Pharma stock price | 0.25 USD |
Previous Close | 3.07 USD |
Open | 3.03 USD |
Bid | 0 USD x 1000 |
Ask | 0 USD x 800 |
Day's Range | 2.99 - 3.08 USD |
52 Week Range | 2.22 - 9 USD |
Volume | 212.18K USD |
Avg. Volume | 216.7K USD |
Market Cap | 115.37M USD |
Beta (5Y Monthly) | 2.831391 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.52 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.5 USD |
ATHA Valuation Measures
Enterprise Value | -60048536 USD |
Trailing P/E | N/A |
Forward P/E | -0.87356323 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 0.5464677 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | 0.604 |
Trading Information
Athira Pharma Stock Price History
Beta (5Y Monthly) | 2.831391 |
52-Week Change | -64.65% |
S&P500 52-Week Change | 20.43% |
52 Week High | 9 USD |
52 Week Low | 2.22 USD |
50-Day Moving Average | 2.84 USD |
200-Day Moving Average | 3.1 USD |
ATHA Share Statistics
Avg. Volume (3 month) | 216.7K USD |
Avg. Daily Volume (10-Days) | 313.56K USD |
Shares Outstanding | 37.95M |
Float | 28.14M |
Short Ratio | 13.33 |
% Held by Insiders | 1.79% |
% Held by Institutions | 75.21% |
Shares Short | 2.05M |
Short % of Float | 7.40% |
Short % of Shares Outstanding | 5.41% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -22.99% |
Return on Equity (ttm) | -39.94% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -99472000 USD |
Net Income Avi to Common (ttm) | -102479000 USD |
Diluted EPS (ttm) | -2.77 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 185.98M USD |
Total Cash Per Share (mrq) | 4.9 USD |
Total Debt (mrq) | 1.83M USD |
Total Debt/Equity (mrq) | 0.87 USD |
Current Ratio (mrq) | 9.573 |
Book Value Per Share (mrq) | 5.563 |
Cash Flow Statement
Operating Cash Flow (ttm) | -82091000 USD |
Levered Free Cash Flow (ttm) | -42450376 USD |
Profile of Athira Pharma
Country | United States |
State | WA |
City | Bothell |
Address | 18706 North Creek Parkway |
ZIP | 98011 |
Phone | 425 620 8501 |
Website | https://www.athira.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 63 |
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton, a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an orally available, brain-penetrant small molecule positive modulator of HGF/MET which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Q&A For Athira Pharma Stock
What is a current ATHA stock price?
Athira Pharma ATHA stock price today per share is 0.25 USD.
How to purchase Athira Pharma stock?
You can buy ATHA shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Athira Pharma?
The stock symbol or ticker of Athira Pharma is ATHA.
Which industry does the Athira Pharma company belong to?
The Athira Pharma industry is Biotechnology.
How many shares does Athira Pharma have in circulation?
The max supply of Athira Pharma shares is 39.04M.
What is Athira Pharma Price to Earnings Ratio (PE Ratio)?
Athira Pharma PE Ratio is now.
What was Athira Pharma earnings per share over the trailing 12 months (TTM)?
Athira Pharma EPS is -2.52 USD over the trailing 12 months.
Which sector does the Athira Pharma company belong to?
The Athira Pharma sector is Healthcare.
Athira Pharma ATHA included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
NASDAQ Global Select Market Com NQGS | 7625.89 USD — |
-5.84
|
— — | 7621.56 USD — | 7894.21 USD — | — - | — — |
NASDAQ Biotechnology NBI | 3904.12 USD — |
-5.49
|
— — | 3901.51 USD — | 4064.61 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}